Clinical Trial Update: Scipibaimab Combined With Tislelizumab in Patients With First-Line Treatment-Failed Recurrent/Metastatic Nasopharyngeal Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the combination of Scipibaimab and tislelizumab for first-line treatment-failed recurrent/metastatic nasopharyngeal carcinom…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• Scipibaimab
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Nasopharyngeal Carcinoma (NPC) | Phase 2 | Status: NOT_YET_RECRUITING